Prostate cancer screening and mortality: a case-control study (United States)

Area of Science:

• Urology
• Oncology
• Public Health

Background:

• Prostate cancer remains a significant cause of mortality in men.
• Screening methods like digital rectal examination (DRE) and prostate-specific antigen (PSA) testing are used to detect prostate cancer.
• The association between screening and prostate cancer mortality requires further investigation.

Purpose of the Study:

• To evaluate the relationship between DRE and PSA testing, individually and combined, and prostate cancer mortality.
• To assess the impact of prostate cancer screening on mortality rates within a specific healthcare system.

Main Methods:

• A case-control study was conducted using data from Kaiser Permanente Northwest (KPNW) members.
• 171 KPNW members who died from prostate cancer (cases) were compared to 342 matched controls.
• Screening history (DRE and PSA) was retrieved from medical records and laboratory databases.

Main Results:

• Prostate cancer screening (DRE and/or PSA) occurred in 69.0% of cases and 74.6% of controls.
• Adjusted logistic regression revealed an inverse association between screening and prostate cancer mortality (OR: 0.70, 95% CI: 0.46 - 1.1).
• The study could not isolate the effect of PSA screening due to the prevalence of DREs.

Conclusions:

• Men who received prostate cancer screening demonstrated a reduced risk of mortality from the disease.
• The findings suggest a potential survival benefit associated with prostate cancer screening.
• Further research is needed to clarify the independent contributions of different screening modalities.